(HealthDay News) – Parenterally administered testosterone injections in overweight or obese men with low testosterone levels lead to significant weight loss and improved waist circumference, blood pressure, and metabolic parameters, according to a study presented at the European Congress on Obesity, held from May 9–11 in Lyon, France.
Farid Saad, MD, of Bayer Pharma in Berlin, and colleagues conducted a prospective study involving 251 men aged 38–83 (mean age, 60.6 years) with testosterone levels between 0.14ng/mL–3.4ng/mL who were treated with parenteral testosterone undecanoate 1,000mg for 12 weeks. Of the cohort, 214 men were followed for two years or more, and 115 were followed for five years or more.
After five years of treatment, the researchers found that average weight decreased from 106.27kg to 90.04kg; waist circumference from 107.21cm to 98.43cm; body mass index from 33.95kg/m² to 29.17kg/m²; serum cholesterol from 281mg/dL to 188mg/dL; low-density lipoprotein from 163mg/dL to 109mg/dL; triglycerides from 276mg/dL to 189mg/dL; glucose from 103mg/dL to 94mg/dL; and systolic and diastolic blood pressure from 153mmHg to 137mmHg and 93mmHg to 79mmHg, respectively.
“Raising serum testosterone to normal reduced body weight, waist circumference, and blood pressure, and improved metabolic profiles. These improvements were progressive over the full five years of the study,” the authors conclude.
Several authors disclosed financial ties to pharmaceutical companies, including Bayer Pharma, which paid for structuring and analyzing of the database.